Skip to main content
. 2011 Mar 4;6(3):e17449. doi: 10.1371/journal.pone.0017449

Figure 1. MYC amplification co-occurs with AKT pathway activation in human prostate tumor samples.

Figure 1

Contingency tables for co-occurrence of MYC and PI3K-pathway copy-number-alterations (defined by aCGH) from 157 primary and 37 metastatic prostate tumor samples. Indicated in red is the proportion of tumors (n = 194 total) with PIK3CA amplification (left) or general PI3K-pathway gain (right) that also exhibit single- or multi-copy MYC gain. Statistical significance for each association is reported as a P-value (2-tailed Fisher's exact test).